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1607-551X/Copyright ª 2014, KaohsiuAbstract The tolerance of mycophenolate mofetil (MMF; Shanghai Roche, China) in Lee Clas-
ses III, IV, and V immunoglobulin A nephropathy (IgAN) remains unclear. This article reports
nine cases of severe pneumonia (SP), including pneumocystis pneumonia (PCP) and cytomeg-
alovirus (CMV) pneumonia, and its risk factors in MMF plus low-dose corticosteroid-treated pa-
tients with Lee Classes III, IV, and V IgAN. Fifty-three patients with IgAN were included in this
single-center study. The treatment regimen was MMF (1e1.5 g/d) plus low-dose corticosteroids
(0.5 mg/kg/d). SP was defined as diffuse bilateral lung infiltrate with respiratory failure. PCP
was diagnosed by detecting the organisms in the sputum and bronchoalveolar lavage. CMV
infection was diagnosed through serum screening for CMV-IgG and IgM antibodies and CMV-
DNA testing by a real-time polymerase chain reaction assay. The risk factors of SP were
analyzed. Nine cases (16.9%) of SP occurred in this study. All SP developed at approximately
the 10the14th week after the initiation of the regimen: PCP was diagnosed in four cases and
CMV infection in two cases. Renal function impairing was more serious in patients with SP than
in those without SP, as evidenced by estimated glomerular filtration rate (p Z 0.019) and
serum creatinine level (p Z 0.016). Six of the nine SPs occurred in MMP plus low-dose meth-
ylprednisolone group, which was statistically higher than that in the MMF plus low-dose pred-
nisone group (p Z 0.000). The incidence of SP in this study was 16.9%. Chronically impaired
renal function and the use of methylprednisolone may be the risk factors for SP.
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Mycophenolate mofetil (MMF; Shanghai Roche, China) has
selective inhibitory effects on proliferative T- and B-lym-
phocytes [1]. Several prospective randomized, controlled
trials have proven the effectiveness of MMF in immuno-
globulin A nephropathy (IgAN) [2,3]. Most clinical trials have
shown that MMF is well tolerated and possesses potent
activity against pneumocystis pneumonia (PCP) [4]. Until
this study, although one study [5] concerning the fact that
severe infections, especially PCP, could occur following
MMF administration has been reported, the tolerance of
MMF combined with low-dose corticosteroids in Lee Classes
III, IV, and V IgAN still remains unknown. To further eval-
uate the occurrence of severe pneumonia (SP) and the
clinical characteristics in Chinese patients classified as
having Lee Classes III, IV, and V IgAN and treated with MMF,
this retrospective cohort study was performed in patients
with IgAN who received either MMF plus low-dose methyl-
prednisolone (MP) or MMF combined with low-dose predni-
sone during the same follow-up period from 2006 to 2012.Table 1 Demographic and clinical data for patients with
Lee Classes III, IV, V IgAN in the mycophenolate mofetil plus
low-dose methylprednisolone and mycophenolate mofetil
combined with low-dose prednisone groups.





group (n Z 35)
p
Age (y) 38.3  11.9 36.9  11.6 0.433
Sex (M:F) 11:7 19:16 0.767
SCr (mmol/L) 232.16  103.9 228.6  101.8 0.338
eGFR (mL/min/
1.73 m2)
39.93  11.63 43.06  12.16 0.381
Urine protein
excretion (g/d)
3.14  1.72 3.30  1.66 0.631
Values expressed as mean  standard deviation. There were no
significant differences in baseline characteristics between the
groups.
eGFR Z estimated glomerular filtration rate; IgAN, immuno-
globulin A nephropathy; MMF Z mycophenolate mofetil;
MP Z methylprednisolone; SCr Z serum creatinine.Materials and methods
Patients and data
This retrospective study evaluated 53 primary Chinese pa-
tients with IgAN, as determined by biopsy, who were regis-
tered for a follow-up examination in our renal center.
Eighteen patients received MMF plus low-dose MP (0.5 mg/
kg/d), whereas the remaining 35 patients received MMF plus
low-dose prednisone (0.5 mg/kg/d). MMF was initiated with
1e1.5 g/d for 6 months, 0.5e1.0 g/d for the next 6 months,
and then 0.25e0.5 g/d for the previous 6 months. Prednisone
was initiated with 0.5 mg/kg/d for 2 months, then slowly
tapered by 5 mg every 2 weeks until discontinuation (the
usage of MP was the same as that of prednisone in the cur-
rent study). The records of the patients were reviewed from
the start of the treatment through the time when the chart
was reviewed, and until the drug was discontinued or severe
infection appeared (final time point). Baseline characteristics
including age, sex, 24-hour urine protein excretion, serum
creatinine, and estimated glomerular filtration rate (eGFR;
according to the modified Modification of Diet in Renal Dis-
ease (MDRD) equation for Chinese [6]) were recorded. SP was
defined as diffused bilateral lung infiltrate with respiratory
failure (PO2 < 60 mmHg). PCP was diagnosed by detecting
the organism in the sputum and bronchoalveolar lavage (BAL)
[7]. CMV infection was diagnosed through serum screening for
CMV-IgG and IgM antibodies. CMV-DNA testing was carried out
by a real-time polymerase chain reaction assay.
This study was conducted in accordance with the Decla-
ration of Helsinki and with approval from the Ethics Commit-
tee of Shenzhen SecondPeople’s Hospital, Guangdong, China.
Written informed consent was obtained from all participants.
Statistical analysis
The clinical characteristics and occurrence of SP were
compared between the MMF plus MP group and the MMFplus prednisone group. The results are given as
mean  standard deviation for descriptive statistics. The
baseline clinical variables were compared using the Student
t test between groups, and the Chi-square test was used for
the comparison of stratified data. SPSS version 13.0 soft-
ware (SPSS Inc., Chicago, IL, USA) was used in all analyses.
A p value < 0.05 was considered significant.
Results
Baseline characteristics
Fifty-three patients with IgAN were registered in our renal
center, and received follow-up examinations from 2006 to
2012. Among these patients, 18 (34%) were treated with
MMF plus low-dose MP, whereas 35 (66%) were treated with
MMF combined with low-dose prednisone. The two groups
did not differ in terms of their distribution of age, sex,
serum creatinine, eGFR, and urine protein excretion at the
baseline (Table 1).
Treatment efficacy
MMF plus low-dose MP or MMF combined with low-dose
prednisone reduced the urine protein excretion and pre-
served the renal function in the present study. At the 12th
month of follow-up, urine protein excretion decreased
greatly from3.14 1.72 g/d to 0.96 0.32 g/day (pZ 0.000),
and the renal function remained stable (serum creatininewas
232.16 103.9 mmol/L and 206.33 79.5 mmol/L prior to and
after the treatment, respectively, pZ 0.245) in the MMF plus
MP group. Meanwhile, urine protein excretion decreased
greatly from3.30 1.66 g/day to 0.31 0.23 g/d (pZ 0.000),
and renal function remained stable (serum creatinine was
228.6  101.8 mmol/L and 201.3  99.3 mmol/L prior to and
after the treatment, respectively, pZ 0.035) in the MMF plus
prednisone group.
Table 3 Clinical characteristics of patients with and
without severe pneumonia.
Characteristics Patients with
SP (n Z 9)
Patients
without
SP (n Z 44)
p
Age (y) 41.7  166 39.7  11.6 0.073
Sex (M:F) 5:4 26:18 0.903
SCr (mmol/L) 263.36  112.3 112.77  63.1 0.016
eGFR (mL/min/
1.73 m2)
41.3  14.2 65.3  30.6 0.019
Urine protein
excretion (g/d)
3.86  1.19 4.01  1.34 0.551
MMF dosage (g/d) 1.33  0.21 1.38  0.19 0.283
eGFR Z estimated glomerular filtration rate;
MMF Z mycophenolate mofetil; PCP Z pneumocystis pneu-
monia; SCr Z serum creatinine; SP Z severe pneumonia.
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Among the 53 patients treated with MMF and low-dose
corticosteroids, nine developed SP around the 3rd month
(10the14th week) after treatment. Six of these nine patients
with SP occurred in the MMP plus low-dose MP group, which
was statistically higher than that in the MMF plus low-dose
prednisone group (33.3%% vs. 8.6%, p Z 0.000). The nine
patients that developed delayed SP after MMF plus low-dose
corticosteroid treatment had fevers > 38C, dry cough, and
progressive dyspnea, as outlined in (Table 2). Chest radi-
ography and computed tomography demonstrated diffuse,
bilateral interstitial, and alveolar infiltrates. All the nine
patients had acute onset and progressed respiratory failure
in 4e7 days. All patients had hypoxemia with arterial
PO2 < 60 mmHg (range: 41e56 mmHg). Two patients died of
respiratory failure after 7e10 days of fever, dry cough, and
progressive dyspnea. The other seven patients recovered.Clinical characteristics
Renal function impairing was more serious in patients with
SP than in those without SP, as evidenced by eGFR
(41.3  14.2 mL/min/1.73 m2 vs. 65.3  30.6 mL/min/
1.73 m2, respectively, p Z 0.019) and serum creatinine
(263.36  112.3 vs. 112.77  63.1, respectively, pZ 0.016;
Table 3). The other index did not exhibit statistical
difference.Microbial etiology
Human immunodeficiency virus screening was negative in
all the nine patients. Six of the nine patients with SP were
transferred to Guangzhou Institute of Respiratory Disease,
Guangzhou, China for further treatment. PCP was diag-
nosed in four patients through PCP screening of sputum,
induced by hypertonic sodium chloride and BAL. BAL
revealed an abundance of inflammatory cells, with a pre-
dominance of neutrophils (49e66%). CMV infection was
diagnosed in two patients via serum screening for CMV-IgG
and IgM antibodies and CMV-DNA testing by real-time po-
lymerase chain reaction assay. The microbial etiology of
the other three patients with SP was unclear.Table 2 Clinical data of patients with severe pneumonia.
No. Age (y) Sex eGFR (mL/min/1.73 m2) MMF (g/d)
1 37 Male 29.9 1.5
2 29 Male 43.1 1.0
3 45 Male 41.7 1.5
4 47 Female 39.4 1.0
5 32 Female 49.0 1.5
6 49 Female 51.3 1.5
7 36 Male 38.6 1.5
8 39 Female 41.6 1.5
9 61 Male 38.2 1.5
CMVZ cytomegalovirus; eGFRZ estimated glomerular filtration rate;
SP Z severe pneumonia.Discussion
IgAN is the most common type of glomerulonephritis in the
world [8]. The course of IgAN is variable, and 15e40% of
patients progress to end-stage renal disease over 10e20
years [9]. However, the effectiveness, especially the safety
therapy, for IgAN remains uncertain and curative therapy is
still unavailable [10].
MMF was introduced into clinical practice 10 years ago
[11,12]. Until this report, SP, including PCP and MCV, fol-
lowed with MMF, had rarely been reported in the treatment
of primary renal diseases [13,14]. Many randomized,
controlled studies of lupus glomerulonephritis have shown
that MMF had a good tolerance compared with other im-
munosuppressants [15]. In four controlled human trials,
none of the 1068 renal transplant recipients that received
MMF developed PCP [16]. In a retrospective study, PCP and
MCV did not occur in 272 renal transplant recipients treated
with MMF [4].
MMF was first used to treat IgAN in 1997 [17]. To date,
four randomized controlled trials have shown good safety
profile in patients with IgAN [2,3,18,19]. However, in a
retrospective study [5], six patients had SP in 32 MMF-
treated patients with IgAN, (3 patients with PCP and 2 pa-
tients suspected of having PCP), compared with thoseTime for SP after MMF (wk) Onset Cause of SP Prognosis
11 Acute PCP Survived
10 Acute PCP Survived
14 Acute not clear Died
13 Acute CMV Survived
12 Acute CMV Survived
13 Acute not clear Survived
11 Acute not clear Survived
12 Acute PCP Survived
13 Acute PCP Died
MMFZmycophenolate mofetil; PCPZ pneumocystis pneumonia;
Treatment of IgA nephropathy 45treated with cyclophosphamide and low-dose prednisone.
Moreover, the patients with SP had a very poor prognosis;
five of six patients presented with an abrupt onset that
rapidly progressed to respiratory failure; three patients
died despite receiving intensive trimethoprim-
sulfamethoxazole therapy. The authors of this retrospec-
tive study thought that the chronically impaired renal
function may be a risk factor for SP in their patients with
IgAN [5].
However, the safety of MMF combined with low-dose
prednisone in IgAN remains unclear. In this study, the
incidence of SP in patients with IgAN treated with MMF
combined with low-dose corticosteroids was 16.9%, similar
to that reported in the literature [5]. The microbial etiology
of SP included PCP and CMV, which was a bit different from
the article reported previously [5]. All the nine patients
presented with an abrupt onset of symptoms that rapidly
progressed to respiratory failure; Two patients died (mor-
tality rate was 22.2%). The prognosis was even worse than
that of AIDS patients with PCP [7].
To date, the related factors of SP in MMF combined with
low-dose prednisone regimen in IgAN are still not well
known. Reduced renal function has been strongly associ-
ated with the occurrence of SP [5]. In the current study,
renal function impairing was also found to be more statis-
tically serious in patients with SP than in those without SP,
as evidenced by eGFR and serum creatinine. This finding
may be due to the pharmacokinetic characteristics of MMF.
The pharmacokinetics of MMF in patients with end-stage
renal disease indicated that renal failure prolongs the
half-life of glucuronide, causing the accumulation of the
mycophenolic acid glucuronide (MPAG) and increasing the
free non-protein-bound fraction of mycophenolic acid
(MPA) (f-MPA) [18e21]. All of the instances of SP occurred
on the 10the14th week of MMF treatment, suggesting that f-
MPA and MPAG accumulated in patients when renal function
was damaged. Thus, pharmacokinetic analysis in different
stages of renal damage deserves further evaluation in
future studies. MMF may be prescribed by adjusting the
dosage according to the renal function.
The incidence of SP in MMP plus low-dose MP group was
statistically higher than that in the MMF combined with low-
dose prednisone group, which has not been previously re-
ported. According to the literature [22], in vitro, the
relative immunosuppressive potency of prednisone is zero,
whereas the MP’s immunosuppressive function is 11. Thus,
patients treated with MMF plus MP may be more susceptible
to infection than patients treated with MMF combined with
prednisone. Given the number of patients with SP is only
nine in this study, the further analysis of the relationship
between SP and prednisone or MP is needed. The immu-
nosuppressive mechanisms of glucocorticoids are currently
unclear, but the high T-cell sensitivity may indicate that
glucocorticoids interact with the proliferation of activated
T-lymphocytes [22]. According to the previous study [7],
the decreased numbers of CD4 þ T cells is a strong risk
factor for PCP infection and lymphopenia is associated with
the susceptibility for PCP [5], so, the immune status should
be monitored by testing lymphocytes and CD4 þ T cells.
This retrospective study showed that chronically
impaired renal function and MP are probably the two risk
factors for SP. The microbial etiology mainly was PCP andCMV. Based on this preliminary result, we recommended
that caution should be taken in the administration of MMF
combined with a steroid, especially with MP, in IgAN pa-
tients with renal insufficiencies. If needed, MMF plus
prednisone is safer than MMF plus MP in Lee Class III-V IgAN
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